Holen Sie sich die Stockscreener-App
82.07
2.04%
-1.71
Schlusskurs vom Vortag:
$83.78
Offen:
$84.02
24-Stunden-Volumen:
241.43K
Relative Volume:
0.69
Marktkapitalisierung:
$1.87B
Einnahmen:
$923.71M
Nettoeinkommen (Verlust:
$84.68M
KGV:
20.82
EPS:
3.9419
Netto-Cashflow:
$182.81M
1W Leistung:
-4.60%
1M Leistung:
+0.27%
6M Leistung:
+7.59%
1J Leistung:
+24.16%
1-Tages-Spanne:
$81.97
$85.90
1-Wochen-Bereich:
$81.97
$87.19
52-Wochen-Spanne:
$62.60
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(609) 759-1810
Adresse
104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, MN
Compare ANIP vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
82.07 | 1.87B | 923.71M | 84.68M | 182.81M | 3.9419 |
TAK
Takeda Pharmaceutical Co Adr
|
16.56 | 52.88B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.76 | 42.98B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.95 | 38.37B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.56 | 31.68B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.22B | 3.17B | 1.29B | 1.01B | 27.09 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ANI Pharmaceuticals (ANIP) Recalls HydrOXYzine Solution, Is The Pullback A Valuation Opportunity? - Sahm
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge - Yahoo Finance
Enterprise value to revenue forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP - TradingView
Price to sales forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP - TradingView
Form 144 ANI Pharmaceuticals For: 7 July By Investing.com - Investing.com India
ANIP (ANIP) insider sales reported: Walsh sold 13,973 shares in May 2026 - Stock Titan
Is Stronger Free Cash Flow Signalling a Shift in ANI Pharmaceuticals' Capital Efficiency Story (ANIP)? - Sahm
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $284k in stock - Investing.com Australia
Form 4 ANI Pharmaceuticals Inc For: 6 July By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals (ANIP) CFO sells 3,313 shares after option exercise - Stock Titan
Price to earnings forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP - TradingView
ANI Pharmaceuticals set to report earnings amid estimate cuts - Investing.com
Insider Sell: Stephen Carey Sells Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
ANI Pharmaceuticals (ANIP) CFO Stephen Carey sells 2,850 shares under Rule 10b5-1 plan - Stock Titan
ANI Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ANIP) - TradingView
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple (NASDAQ:ANIP) - Seeking Alpha
ANIP Forecast — Price Target — Prediction for 2027 - TradingView
ANI Pharmaceuticals, Inc. Actuals & Estimates (BOATS:ANIP) - TradingView
ANI Pharmaceuticals (ANIP) Stock Could Be 29.5% Below Fair Value After Recent Pullback - Sahm
ANI Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $114.17, Implies 44% Upside - TradingView
ANI Pharmaceuticals Inc (ANIP) Valuation: PE, PB & Fair Value Analysis - TradingKey
ANI Pharmaceuticals Inc (ANIP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ANI Pharmaceuticals Inc (ANIP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ANI Pharmaceuticals Inc (ANIP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ANI Pharmaceuticals Inc (ANIP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ANI Pharmaceuticals Inc (ANIP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ANI Pharmaceuticals Inc (ANIP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ANI Pharmaceuticals Inc (ANIP) Institutional Confidence - TradingKey
ANI Pharmaceuticals Inc (ANIP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insider Sell: Meredith Cook Sells 500 Shares of ANI Pharmaceuticals Inc (ANIP) - GuruFocus
Ani Pharmaceuticals Sr. VP Cook sells $41,015 in stock - Investing.com UK
Ani Pharmaceuticals Sr. VP Cook sells $41,015 in stock By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals (ANIP) VP sells 500 shares under 10b5-1 plan - Stock Titan
ANI Pharmaceuticals (ANIP) Stock Valuation After Recent Momentum And Cortrophin Growth Prospects - Sahm
Insider Sell: Thomas Haughey Sells 2,000 Shares of ANI Pharmaceu - GuruFocus
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock - Investing.com
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock By Investing.com - Investing.com India
ANI Pharmaceuticals (ANIP) director awarded 4,357 restricted shares vesting in 2027 - Stock Titan
ANI Pharmaceuticals (ANIP) director receives 4,357-share restricted stock award - Stock Titan
ANI Pharmaceuticals (ANIP) director sells 2,000 shares under plan - Stock Titan
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings? - Yahoo Finance
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push - Yahoo Finance
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth - Yahoo Finance
CenterBook Partners LP Purchases Shares of 19,226 ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $264,960 in stock - Investing.com UK
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $264,960 in stock By Investing.com - Investing.com South Africa
[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.42%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):